Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Upcoming Result Date: Mar 08, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Remedium Lifecare Ltd (REMLIFE) is currently trading at 0.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Remedium Lifecare Limited is a pharmaceutical company specializing in trading and selling APIs and intermediates. They operate in both domestic and international markets, including regulated ones. The company changed its name from 'Roxy Exports Limited' to 'Remedium Lifecare Limited' to reflect its updated business focus. In 2021, Remedium Lifecare transitioned from manufacturing Air-O-Water machines to trading API intermediates and contract manufacturing, indicating a strategic realignment. Remedium Lifecare emphasizes innovation in the pharmaceutical industry, focusing on trading advanced intermediates vital for API manufacturing. Its history dates back to 1988, positioning it as an experienced entity in the evolving pharmaceutical sector.
Over the past 52 weeks, Remedium Lifecare Ltd has traded between a low of ₹0.50 and a high of ₹1.94. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Remedium Lifecare Ltd has a market capitalization of approximately 48.51. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Remedium Lifecare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 11.00 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 48.51 Cr, Remedium Lifecare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Remedium Lifecare Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Remedium Lifecare Ltd is 11.00. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The most significant announcement is the 'Biopharma Shakti' initiative, a ₹10,000 crore program designed to boost domestic manufacturing of biologics and biosimilars, which is expected to increase demand for API intermediates traded by the company.
Board Meeting Rescheduling
Supha Pharmachem rescheduled its Board meeting to 9 March 2026 to consider and approve unaudited standalone and consolidated results for the quarter and nine months ended 31 Dec 2025, citing delayed Singapore subsidiary data; trading window remains closed.
Board Meeting Reschedule
Supha Pharmachem rescheduled its Board meeting to 09-Mar-2026 to consider and approve unaudited standalone and consolidated results for quarter and nine months ended 31-Dec-2025, delayed due to missing Singapore subsidiary data; trading window closed.
Bearish
4
Neutral
1
Bullish
9
Bearish
36
Neutral
1
Bullish
9
Bearish
32
Neutral
0
Bullish
0
Remedium Lifecare Limited is a pharmaceutical company specializing in trading and selling APIs and intermediates. They operate in both domestic and international markets, including regulated ones.
The company changed its name from 'Roxy Exports Limited' to 'Remedium Lifecare Limited' to reflect its updated business focus.
In 2021, Remedium Lifecare transitioned from manufacturing Air-O-Water machines to trading API intermediates and contract manufacturing, indicating a strategic realignment.
Remedium Lifecare emphasizes innovation in the pharmaceutical industry, focusing on trading advanced intermediates vital for API manufacturing.
Its history dates back to 1988, positioning it as an experienced entity in the evolving pharmaceutical sector.
Pharmaceuticals
Trading - Medium / Small
49 Cr
Low Risk
11.0
37.7
0.9
0.5
1.94
0.55
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
0.40 | 50 Cr | 0.67 | 0.37 | 0.00 | 7.04 | 9.11 | 4.02 | |
41.00 | 50 Cr | -48.04 | 0.52 | 0.00 | 0.94 | 0.74 | -2.01 | |
54.05 | 50 Cr | 9.70 | 1.06 | 0.00 | 9.52 | 10.76 | 5.12 | |
58.45 | 49 Cr | 1.75 | 3.41 | 0.00 | 29.91 | 18.98 | 107.87 | |
0.55 | 49 Cr | 11.00 | 0.53 | 0.00 | 0.00 | 0.00 | — | |
7.52 | 48 Cr | 32.70 | 6.93 | 0.00 | 12.06 | 14.88 | 16.51 | |
66.50 | 47 Cr | 7.07 | 1.49 | 0.00 | 0.00 | 0.00 | 8.21 |
